Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study

References

• World Health Organization. World Health Report 2003—Shaping the Future. Available from http://www.who.int/entity/whr/2003/en/index.html. Accessed April 2 2008
   Google Scholar
• Rosamond W, Flegal K, Furie K, . Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Committee. Circulation 2008; 29:e25–e146
   Google Scholar
• Ounpuu S, Yusuf S. Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition. Eur Heart J 2003; 24:127–9
   PubMed Web of Science ®Google Scholar
• Khoo KL, Tan H, Liew YM, . Lipids and coronary heart disease in Asia. Atherosclerosis 2003; 169:1–10
   PubMed Web of Science ®Google Scholar
• Ministry of Health China. Statistics 2007. Available at http://english.gov.cn/open/statistics/year2007/p295.htm. [Last accessed 4 February 2008]
   Google Scholar
• Adult Treatment Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143–421
   PubMed Web of Science ®Google Scholar
• Kim S-H, Park J-S, Zo J-H, . Treatment gap in the management of hypercholesterolemia in Korea: Return on Expenditure Achieved for LIpid TherapY (REALITY). Korea Circulation J 2006; 36:593–9
   Google Scholar
• Sung J, Kim SH, Kim Y-D, . Ten Centers’ Study on the present state of treatment for hypercholesterolemia in patients with coronary artery disease. Korean J Med 2005; 69:371–8
   Google Scholar
• KLIS Investigators. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb 2000; 7:110–21
   PubMedGoogle Scholar
• Mizuno K, Nakaya N, Ohashi Y, . Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA Study). Circulation 2008; 117:494–502
   PubMed Web of Science ®Google Scholar
• Nagashima M, Koyanagi R, Kasanuki H, . Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). Am J Cardiol 2007; 99:1523–8
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, . Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368:1155–63
   PubMed Web of Science ®Google Scholar
• Nakamura H. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atheroscler Suppl 2007; 8:13–7
   PubMed Web of Science ®Google Scholar
• Mizuno K, Nakamura H, Ohashi Y, . A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese Utilization of Simvastatin Therapy (JUST) study. Clin Ther 2004; 26:878–88
   PubMed Web of Science ®Google Scholar
• Zhang X, Patel A, Horibe H, . Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32:563–72
   PubMed Web of Science ®Google Scholar
• Zhao L, Liang L, Tian X, . The trends in clinical management of hypercholesterolemia in China: goal attainment from 2000 to 2004-2006 (abstract 87922). Presented at European Society of Cardiology Congress 2007Vienna, AustriaSeptember 1-5, 2007
   Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101:207–13
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720–32
   PubMed Web of Science ®Google Scholar
• Rydén L, Standl E, Bartnik M, . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88–136
   PubMed Web of Science ®Google Scholar
• Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80:106–7
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, . European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375–414
   PubMed Web of Science ®Google Scholar
• EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357:995–1001
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459–67
   PubMed Web of Science ®Google Scholar
• Wood D, De Backer G, Faergeman O. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19:1434–1503
   PubMed Web of Science ®Google Scholar
• Zhu J-R, Tomlinson B, Ro YM, . A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 2007; 23:3055–68
   PubMed Web of Science ®Google Scholar
• Wu YF. The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors. Chin J Cardiol 2007; 35:420–7
   Google Scholar
• Wu Y-F. A multi-center study of current status on clinical control of hypercholesterolemia in China: success rate and related factors. Chin J Cardiol 2002; 30:109–14
   Google Scholar
• Nitiyanant W, Ngamukos P, Koanantakul B. The Lipid Treatment Assessment Project (LTAP) in Thailand. Intern Med J 2001; 17:46–52
   Google Scholar
• Nitiyanant W, Sritara P, Deerochanawong C. The Lipid Treatment Assessment Project II (LTAP-II) in Thailand. Presented at the 15th ASEAN Congress of Cardiology (ACC)Pattaya, ThailandOctober 23-27, 2004
   Google Scholar
• Van Ganse E, Laforest L, Alemao E, . Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21:1389–99
   PubMed Web of Science ®Google Scholar
• Cheng CW, Woo KS, Chan JC, . Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol 2004; 58:528–35
   PubMed Web of Science ®Google Scholar
• Ho KT, Chin KW, Ng KS, . The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs 2006; 6:383–91
   PubMedGoogle Scholar
• Lee VWY, Chan WK, Lee BSC, . Cholesterol goal attainment among CHD patients in Hong Kong. Presented at 6th Annual Quality of Care & Outcomes Research in Cardiovascular Disease and StrokeWashington, DCMay 14–16, 2005
   Google Scholar
• Krobot KJ, Yin DD, Alemao E, . Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005; 12:37–45
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz FJ, Marin IA, Perez-Jimenez F, . Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics 2004; 22 (Suppl 3) 1–12
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, . A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80:587–95
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, . Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149:464–73
   PubMed Web of Science ®Google Scholar
• Cruz-Fernandez JM, Bedarida GV, Adgey J, . Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005; 59:619–27
   PubMed Web of Science ®Google Scholar
• Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007; 23:767–75
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, . Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006; 22:2041–53
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Weiss R, Moccetti T, . Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99:673–80
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Zachry III WM, Malone DC. Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data. J Manag Care Pharm 2004; 10:251–8
   PubMedGoogle Scholar
• Kashyap ML, McGovern ME, Berra K, . Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89:672–8
   PubMed Web of Science ®Google Scholar
• Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296:2563–71
   PubMed Web of Science ®Google Scholar
• Kim S-H, Sung JD, Kim H-S. 2007 Ten Center Follow-up Study. Presented at the Annual Scientific Session of the Korean Circulation Society. September 12, 2007
   Google Scholar